Recombinant VSVs: A Promising Tool for Virotherapy

Area of Science:

• Oncology
• Virology
• Biotechnology

Background:

• Cancer remains a leading global cause of mortality, driving the need for novel therapeutic strategies.
• Current treatments like surgery, radiotherapy, and chemotherapy have limitations, necessitating innovative approaches.
• Oncolytic viruses, such as vesicular stomatitis virus (VSV), are emerging as a promising alternative for cancer treatment.

Purpose of the Study:

• To review the potential of vesicular stomatitis virus (VSV) as an oncolytic agent.
• To discuss VSV's mechanisms of action, oncogenesis, and tumor cell resistance.
• To examine the development and clinical application of VSV-based cancer therapies.

Main Methods:

• Literature review of oncogenesis and antiviral responses.
• Analysis of VSV properties and recombinant VSV production.
• Examination of clinical trial data for VSV virotherapy.

Main Results:

• VSV exhibits oncolytic properties, making it a candidate for cancer therapy.
• Understanding tumor cell resistance and antiviral responses is crucial for VSV efficacy.
• Recombinant VSV can be engineered to enhance its therapeutic potential.

Conclusions:

• VSV-based virotherapy holds significant promise for cancer treatment.
• Further research and clinical trials are necessary to establish VSV as an approved therapy.
• VSV offers a novel approach to targeting and eliminating malignant tumors.